Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast devoted to offering present and future oncologists and hematologists with the data they should ace their boards and ship high quality affected person care. Dr Armstrong is a hematologist/oncologist and assistant professor of medical drugs at Indiana College Well being in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of medical drugs on the College of Illinois in Chicago.
On this episode, OncLive On Air® partnered with Two Onc Docs to deliver you insights on the section 3 ADRIATIC trial (NCT03703297), which investigated durvalumab (Imfinzi) with or with out tremelimumab (Imjudo) vs placebo as consolidation remedy in sufferers with limited-stage small cell lung most cancers (LS-SCLC) who haven’t progressed following concurrent chemoradiotherapy. The findings from the durvalumab monotherapy and placebo arms of this trial have been introduced on the 2024 ASCO Annual Assembly by David R. Spigel, MD, of Sarah Cannon Analysis Institute in Nashville, Tennessee. On this episode, Drs Armstrong and Tawagi reviewed frequent threat components, pathology, presentation, and staging of SCLC; the present customary of look after sufferers with LS-SCLC; and key findings from ADRIATIC that impressed a standing ovation at ASCO.
